CABA - Cabaletta Bio, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Philadelphia,
United States
Type: Equity
CABA price evolution
CABA
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $193.24 | $115.5 | $128.07 | $93.84 |
| Short term investments | $48.01 | $48.89 | $48.26 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $244.49 | $166.18 | $177.57 | $95.73 |
| Long term investments | ||||
| Property, plant & equipment | $7.45 | $6.13 | $6.38 | $7.13 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $9.16 | $7.11 | $7.07 | $7.71 |
| Total investments | $48.01 | $48.89 | $48.26 | |
| Total assets | $253.65 | $173.29 | $184.64 | $103.45 |
| Current liabilities | ||||
| Accounts payable | $4.55 | $3.62 | $2.34 | $3.96 |
| Deferred revenue | ||||
| Short long term debt | $3.56 | $2.52 | $2.18 | $2.18 |
| Total current liabilities | $15.99 | $10.62 | $8.48 | $9.3 |
| Long term debt | $1.46 | $1.75 | $2.01 | $2.49 |
| Total noncurrent liabilities | $1.46 | $1.75 | $2.01 | $2.49 |
| Total debt | $5.02 | $4.27 | $4.2 | $4.67 |
| Total liabilities | $17.45 | $12.36 | $10.5 | $11.8 |
| Shareholders' equity | ||||
| Retained earnings | -$233.24 | -$212.35 | -$195.9 | -$181.42 |
| Other shareholder equity | $0.04 | -$0.02 | -$0 | -$0 |
| Total shareholder equity | $236.2 | $160.92 | $174.14 | $91.65 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $193.24 | $81.61 | $122.22 | $101.43 |
| Short term investments | $48.01 | $24.94 | $7.23 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $244.49 | $108.83 | $124.54 | $113.53 |
| Long term investments | ||||
| Property, plant & equipment | $7.45 | $7.57 | $1.44 | $0.89 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $9.16 | $8.13 | $1.79 | $1.19 |
| Total investments | $48.01 | $24.94 | $7.23 | |
| Total assets | $253.65 | $116.97 | $126.34 | $114.72 |
| Current liabilities | ||||
| Accounts payable | $4.55 | $2.46 | $2.33 | $1.24 |
| Deferred revenue | ||||
| Short long term debt | $3.56 | $2.18 | ||
| Total current liabilities | $15.99 | $9.49 | $8.38 | $5.18 |
| Long term debt | $1.46 | $2.96 | ||
| Total noncurrent liabilities | $1.46 | $2.96 | ||
| Total debt | $5.02 | $5.14 | ||
| Total liabilities | $17.45 | $12.45 | $8.38 | $5.18 |
| Shareholders' equity | ||||
| Retained earnings | -$233.24 | -$165.56 | -$112.59 | -$66.3 |
| Other shareholder equity | $0.04 | -$0.05 | -$0 | $0.01 |
| Total shareholder equity | $236.2 | $104.52 | $117.96 | $109.54 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $17.41 | $13.79 | $11.8 | $12.44 |
| Selling, general & administrative | $5.74 | $4.88 | $4.09 | $4.52 |
| Total operating expenses | $23.15 | $18.67 | $15.89 | $16.96 |
| Operating income | -$23.15 | -$18.67 | -$15.89 | -$16.96 |
| Income from continuing operations | ||||
| EBIT | -$20.89 | -$16.45 | -$14.49 | -$15.85 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$20.89 | -$16.45 | -$14.49 | -$15.85 |
| Income (for common shares) | -$20.89 | -$16.45 | -$14.49 | -$15.85 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $55.42 | $39.3 | $32.49 | $21.38 |
| Selling, general & administrative | $19.24 | $14.84 | $13.82 | $12.46 |
| Total operating expenses | $74.66 | $54.14 | $46.31 | $33.83 |
| Operating income | -$74.66 | -$54.14 | -$46.31 | -$33.83 |
| Income from continuing operations | ||||
| EBIT | -$67.67 | -$52.98 | -$46.29 | -$33.34 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$67.67 | -$52.98 | -$46.29 | -$33.34 |
| Income (for common shares) | -$67.67 | -$52.98 | -$46.29 | -$33.34 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$20.89 | -$16.45 | -$14.49 | -$15.85 |
| Operating activities | ||||
| Depreciation | $1 | $0.85 | $0.83 | $0.82 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.05 | $3.01 | $2.8 | $2.48 |
| Total cash flows from operations | -$16.45 | -$12.6 | -$11.89 | -$12.61 |
| Investing activities | ||||
| Capital expenditures | -$0.18 | -$0.07 | -$0.06 | -$0.38 |
| Investments | $1.32 | -$48.09 | $25 | |
| Total cash flows from investing | $1.14 | -$0.07 | -$48.14 | $24.62 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $93.05 | $0.1 | $94.03 | $0.46 |
| Net borrowings | ||||
| Total cash flows from financing | $93.05 | $0.1 | $94.26 | $0.23 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $77.74 | -$12.57 | $34.23 | $12.24 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$67.67 | -$52.98 | -$46.29 | -$33.34 |
| Operating activities | ||||
| Depreciation | $3.5 | $3.68 | $0.73 | $0.35 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $11.34 | $6.9 | $5.8 | $4.39 |
| Total cash flows from operations | -$53.55 | -$46.38 | -$34.11 | -$26.77 |
| Investing activities | ||||
| Capital expenditures | -$0.69 | -$2.45 | -$1.17 | -$0.64 |
| Investments | -$21.76 | -$24.76 | $7.17 | -$7.35 |
| Total cash flows from investing | -$22.45 | -$27.22 | $6 | -$7.98 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $187.63 | $32.98 | $48.9 | -$0.02 |
| Net borrowings | ||||
| Total cash flows from financing | $187.63 | $32.98 | $48.9 | -$0.02 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $111.63 | -$40.62 | $20.79 | -$34.77 |
News
|
Are Investors Undervaluing Cabaletta Bio, Inc. (NASDAQ:CABA) By 47%?
Simply Wall St. via Yahoo Finance
10 Jan 2024
|
|
Top Stocks for December 2023
Investopedia
1 Dec 2023
|
|
Cabaletta Bio’s and Gracell’s stock falls sharply as FDA investigates risks of CAR-T therapy
Market Watch
28 Nov 2023
|
|
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's...
Investing.com
28 Nov 2023
|
|
Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?
Zacks via Yahoo Finance
9 Oct 2023
|
|
Pleasing Signs As A Number Of Insiders Buy Cabaletta Bio Stock
Simply Wall St. via Yahoo Finance
2 Oct 2023
|
|
What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing'
Zacks via Yahoo Finance
25 Sep 2023
|
|
Cabaletta Bio, Inc. (CABA) is on the Move, Here's Why the Trend Could be Sustainable
Zacks via Yahoo Finance
8 Sep 2023
|
|
Top Growth Stocks for September 2023
Investopedia
1 Sep 2023
|
|
Top Stocks for September 2023
Investopedia
1 Sep 2023
|
Fundamentals
| Market cap | $538.49M |
|---|---|
| Enterprise value | $350.27M |
| Shares outstanding | 47.82M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$64.18M |
| EBIT | -$67.67M |
| Net Income | -$67.67M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -7.96 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -5.46 |
| EV/EBIT | -5.18 |
| P/S ratio | N/A |
| P/B ratio | 2.28 |
| Book/Share | 4.94 |
| Cash/Share | 4.04 |
| EPS | -$1.42 |
|---|---|
| ROA | -37.86% |
| ROE | -40.83% |
| Debt/Equity | 0.07 |
|---|---|
| Net debt/EBITDA | 2.74 |
| Current ratio | 15.29 |
| Quick ratio | 15.29 |